

CHOLESTEROL

From Chemistry and
Biophysics to the Clinic



Edited by
Anna N. Bukiya, PhD
Alex M. Dopico, MD, PhD



CHOLESTEROL

CHOLESTEROL

From Chemistry and Biophysics to the Clinic

Edited by

ANNA N. BUKIYA

*Professor, Department of Pharmacology, Addiction Science and Toxicology, College of Medicine,
The University of Tennessee Health Science Center, Memphis, TN, United States*

ALEX M. DOPICO

*Van Vleet Chair of Excellence, Department of Pharmacology, Addiction Science and Toxicology, College of Medicine,
The University of Tennessee Health Science Center, Memphis, TN, United States*



ACADEMIC PRESS

An imprint of Elsevier

Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1650, San Diego, CA 92101, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom

Copyright © 2022 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN 978-0-323-85857-1

For information on all Academic Press publications
visit our website at <https://www.elsevier.com/books-and-journals>

Publisher: Stacy Masucci
Acquisitions Editor: Peter B. Linsley
Editorial Project Manager: Barbara L. Makinster
Production Project Manager: Selvaraj Raviraj
Cover Designer: Vicky Pearson Esser

Typeset by STRAIVE, India



Contents

Contributors xiii

Preface xvii

Afterword xix

SECTION 1

Cholesterol chemistry and cell function

1. Cholesterol chemistry and laboratory synthesis

Hélio M.T. Albuquerque, Clementina M.M. Santos,
and Artur M.S. Silva

Introduction 4

Cholesterol structural characterization 6

Cholesterol laboratory synthesis 9

Concluding remarks 21

References 22

2. Molecular evolution of cholesterol and other higher sterols in relation to membrane structure

Ole G. Mouritsen

Introduction: The overlooked lipids 25

Key features of the cholesterol molecule 27

Evolution and streamlining of a molecule 27

Phase equilibria in lipid membranes 29

Cholesterol and lipid membrane phase equilibria:

The liquid-ordered phase 30

Cholesterol, transverse membrane order, permeability,
and mechanics 32

Cholesterol and lateral membrane organization 33

Other higher sterols: Universality in sterol
function 35

A case study: Cholesterol, lateral membrane structure,
and the functioning of Na^+/K^+ -ATPase 36

Cholesterol and membrane evolution 36

References 38

3. Role of cholesterol in maintaining the physical properties of the plasma membrane

Witold K. Subczynski, Marta Pasenkiewicz-Gierula,
Justyna Widomska, and Natalia Stein

Introduction 42

Phase diagram for cholesterol/phospholipid mixtures 43

Basic membrane physical properties and how
cholesterol regulates them 45

Lateral organization of membranes: Effect of
cholesterol 57

New information from the saturation recovery
electron paramagnetic resonance stretched
exponential function approach 59

Concluding remarks 61

Summary 64

References 64

4. The fundamental interaction of cholesterol with lipid membranes: The umbrella model

Juyang Huang

Introduction 73

Maximum solubility of cholesterol
in phosphatidylcholine (PC) and
phosphatidylethanolamine (PE) bilayers 74

The umbrella model 77

Monte Carlo simulation of chemical potential of
cholesterol using multibody interactions 81

A family of small headgroup molecules: Sterols,
ceramides, and diacylglycerols 85

Molecular dynamics (MD) simulation of the umbrella
effect 87

Measurement of the chemical potential of cholesterol
in PC bilayers 90

Concluding remarks 95

References 96

5. Model peptides and cholesterol

István P. Sugár and Parkson Lee-Gau Chong

On the energy and entropy parameters of the free energy of the membrane 107

References 109

6. Cholesterol and ceramide: An unlikely pair

Aritz B. García-Arribas, Alicia Alonso, and Félix M. Goñi

Introduction: Membrane heterogeneity 111

Sphingolipids and cholesterol: Biological impact 112

Sphingolipids and cholesterol: Membrane biophysics 114

Cholesterol and ceramide in fluid membranes 117

Conclusions and future perspectives 123

References 123

7. Cholesterol-recognizing amino acid consensus motifs in transmembrane proteins: Comparative analysis of in silico studies and structural data

Fodil Azzaz, Henri Chahinian, Nouara Yahi, Coralie Di Scala, Carlos J. Baier, Francisco J. Barrantes, and Jacques Fantini

Introduction 127

Cholesterol: Bifacial structure, multifaceted functions 128

Cholesterol footprint on a membrane protein: Starting the investigation 130

CARC and CRAC algorithms: Basic principles at work 132

Cholesterol-binding motifs in 3D: What structural studies reveal 134

Moving to the 3rd dimension 139

Conclusion 140

References 141

8. Effects of cholesterol on the GPCR AT1 receptor and its interplay with AT1 antagonists

Sofia Kiriakidi, Zoe Cournia, and Thomas Mavromoustakos

Introduction 148

Experimental results and their discussion 156

Cholesterol influence on the physicochemical properties of the cell membrane in the presence of AT1R and sartans 160

Molecular dynamics (MD) simulations on AT1R embedded in a DPPC:Cholesterol (60:40mol%) bilayer reveal a putative binding site for AT1R blockers on the receptor 161

Conclusions 162

References 163

9. Principles of cholesterol regulation of ion channels

Qiu-Xing Jiang and Irena Levitan

Introduction 169

Lipids as structural components and functional regulators of membrane proteins 173

A thermodynamic consideration of lipid-binding sites on ion channels and their generic effects on the gating of the channels 175

Cholesterol-binding sites on ion channels 177

Functional impact of cholesterol on the activities of ion channels 186

Technical limitations and potential solutions for further developments 195

Conclusions 197

References 198

10. Fluorescent probes for microscopy visualization of cholesterol topography and dynamics in membranes

Francisco J. Barrantes

Introduction 206

The elusive ideal probe 208

Cholesterol probes 208

Indirect cholesterol probes 209

Direct imaging of intrinsic fluorescent cholesterol analogs 211

Concluding remarks 219

References 220

11. Cholesterol transport in blood, lipoproteins, and cholesterol metabolism

Mark T. Mc Auley and Amy E. Morgan

Introduction 228

Lipoproteins an overview 230

Low-density lipoprotein cholesterol 235

High-density lipoprotein cholesterol 236

How does aging impact cholesterol metabolism? 238

Obesity and aging: Two sides of the same coin? 240

Using mathematical modeling to explore cholesterol metabolism 242

Discussion of future perspectives 245
References 247

12. Common laboratory research methods for detection and quantification of cholesterol

Anna N. Bukiya, Hanxuan Li, Steven Mysiewicz, and Wei Li

Introduction to cholesterol detection and quantification 259
The early era of cholesterol detection and quantification: Colorimetric approaches 262
MS-based approaches 264
Imaging-based approaches 270
Enzymatic methods 276
Summary and concluding remarks 279
References 280

13. Approaches for modifying cellular cholesterol levels and their application to mechanistic studies: Examples from the ion channel field

Avia Rosenhouse-Dantsker, Alexandria Slayden, and Anna N. Bukiya

Introduction 290
In vitro methods for modifying cholesterol levels in cell membranes 291
In vivo modification of cholesterol levels 303
Applications to mechanistic studies on the effect of cholesterol on ion channel targets 312
Outlook 319
References 320

SECTION 2

Cholesterol homeostasis and its disruption

14. Diet-induced hypercholesterolemia in small laboratory animal models

Tina Herfel

Introduction 343
Mouse models 344
Rat models 348
Hamsters 349
Guinea pigs 352
Rabbits 354
Additional diet considerations 356

Control diets 358
References 359

15. Nutrition and cholesterol metabolism

Ghada A. Soliman

Introduction 372
Cholesterol structure 373
Nutritional recommendations for maintaining healthy blood cholesterol levels 374
Dietary cholesterol intake 375
Saturated fat intake 377
Cholesterol functions 381
Digestion and absorption of cholesterol 381
Transport of cholesterol 382
Endogenous cholesterol synthesis 384
Blood cholesterol and atherosclerosis 385
Guinea pigs as a preclinical model 386
Advances in cholesterol research 387
Explanatory and predictive models approach 393
Conclusions 394
References 396

16. Cholesterol and early development

Isabella Ellinger and Waranya Chatuphonprasert

Introduction 404
The fetus and cholesterol 406
Steroid hormones in reproduction and early life 414
Extraembryonic structures, secondary yolk sac and placenta, and materno-fetal cholesterol transport 422
Maternal cholesterol levels in healthy pregnancies, maternal hyper- and hypocholesterolemia, and consequences for the fetus 426
Effect of selected medicines related to cholesterol metabolism on the fetal development 430
Summary 436
References 437

17. Clinical and biochemical diagnostic methods: What do blood lipid levels tell us?

Marshall B. Elam

Introduction 452
Use of conventional laboratory methods to measure lipoproteins by determining their cholesterol content 454
Beyond standard lipid profiles: Determination of atherogenic lipoproteins by advanced lipoprotein testing 454

Fasting versus nonfasting lipid measurements	458
Lipid and lipoprotein testing in laboratory animals	460
What do lipid/lipoprotein levels tell us?	460
References	462

18. Familial hypobetalipoproteinemia and abetalipoproteinemia

Francine K. Welty

Introduction	465
ApoB gene mutations causing familial hypobetalipoproteinemia	466
Familial hypobetalipoproteinemia (FHBL) and coronary heart disease (CHD)	468
FHBL and hepatic steatosis	468
FHBL and insulin sensitivity	469
FHBL, hepatic cirrhosis, and hepatocarcinoma	470
FHBL and psychiatric disease	470
Heterozygous FHBL and neurological manifestations	471
Proprotein convertase subtilisin kexin 9 gene (PCSK9) mutations	471
Familial combined hypolipidemia (FHBL2)	471
ANGPTL3 S17X	472
Abetalipoproteinemia (ABL) and homozygous hypobetalipoproteinemia (HHBL)	473
Diagnosis and management	473
Heterozygous FHBL	474
Pregnancy management	477
Conclusion	477
References	477

19. Critical illness and cholesterol levels

Zdenek Zadak

Introduction	481
Clinical implications of hypocholesterolemia	488
References	496

20. Familial hypercholesterolemia

Shifa Jebari-Benslaïman, Unai Galicia-Garcia, Asier Larrea-Sebal, Kepa B. Uribe, Cesar Martin, and Asier Benito-Vicente

Introduction	502
Genetic and molecular background of FH	502
Familial hypercholesterolemia diagnosis	507
Familial hypercholesterolemia treatments	509
Nutrition and familial hypercholesterolemia	513

Management of homozygous familial hypercholesterolemia	514
Familial hypercholesterolemia-related diseases	514
Familial hypercholesterolemia current status and future perspectives	516
References	517

21. Niemann-Pick type C disease (NPC)

Agnieszka Lugowska

Introduction	525
Clinical picture of NPC disease	527
Genetic background of NPC	528
Biochemical aspects of NPC1 and NPC2 proteins	532
Pathomechanisms underlying NPC disease	535
Diagnostics	538
Treatment	543
References	544

22. Rare monogenic disorders of cholesterol metabolism

Małgorzata Bednarska-Makaruk and Agnieszka Lugowska

Introduction	555
Monogenic hypercholesterolemia	555
Sterol storage diseases	569
Bile acid biosynthesis disorders	576
Hypocholesterolemia	583
References	598

23. Secondary (acquired) hypercholesterolemia

Arrigo F.G. Cicero and Ivan R. Cincione

Introduction	609
Causes of secondary hyperlipidemias and their treatment	610
Conclusions	616
References	616

24. Blood lipids and molecular pathways of atherogenesis

Ricardo Stein, Filipe Ferrari, and Vítor M. Martins

Introduction	624
Cholesterol metabolism	625
Pathophysiology of atherosclerosis	626

Low-density lipoprotein cholesterol and cardiovascular disease 626
 Oxidized low-density lipoprotein cholesterol and cardiovascular disease 627
 High-density lipoprotein cholesterol: Marker or risk factor? 630
 Triglycerides and cardiovascular disease 631
 Genetics and dyslipidemia 632
 Conclusions 633
 References 633

25. Lysosomal acid lipase: Roles in rare deficiency diseases, myeloid cell biology, innate immunity, and common neutral lipid diseases

Gregory A. Grabowski and Hong Du

Historical background: Lysosomal acid lipase (LAL) 640
 Structure, properties, and biology of LAL 641
 LAL roles in disease states 652
 Molecular biology and genetics 657
 LAL in diseases beyond the LALDs 662
 References 664

26. Cholesterol and pathogens

Tatiana M. Clemente and Stacey D. Gilk

Introduction 676
 The role of cholesterol-rich membrane microdomains in infectious diseases 676
 Cholesterol recruitment to pathogen-containing vacuoles 681
 Targeting cellular cholesterol metabolism 684
 Systemic cholesterol levels and pathogens 687
 Cholesterol-lowering agents as potential therapeutics in infectious diseases 690
 Cholesterol and immune response 692
 Summary 696
 References 697

27. Involvement of cholesterol and β -amyloid in the initiation and progression of Alzheimer's disease

Luis G. Aguayo, Jorge P. Roa, Carlos F. Burgos, and Juliana Gonzalez-Sanmiguel

Neurodegenerative diseases are a significant health problem: Alzheimer's disease (AD) 716

The amyloid cascade as a central cause for Alzheimer's disease 718
 Cellular domains important for the formation of A β and cholesterol 720
 Interactions of A β with the neuronal membrane and the initiation of synaptic failure 723
 Participation of membrane lipids in the initiation of A β -mediated neurotoxicity 725
 How A β and cholesterol might lead to neurodegeneration 729
 Cholesterol affects a number of membrane proteins that fine tune neuronal excitability 730
 The ϵ 4 isoform (ApoE4) factor in disease onset and progression 733
 References 736

28. Cholesterol and alcohol

Andrew S. Bell, Emma M. O'Connell, and Falk W. Lohoff

Introduction 747
 Alcohol pharmacology 748
 Alcohol use disorder 749
 Alcohol and cholesterol interactions 750
 Alcohol and lipoproteins 751
 Alcohol and PCSK9 753
 Fetal alcohol spectrum disorders (FASDs) and cholesterol 755
 Targeting lipids for treatment of alcohol-related diseases 757
 Conclusion 760
 References 760

SECTION 3

Pharmacological considerations and perspectives

29. Cholesterol stiffening of lipid membranes and drug interactions: Insights from neutron spin echo and deuterium NMR spectroscopy

Sudipta Gupta, Fathima T. Doole, Teshani Kumarage, Milka Doktorova, George Khelashvili, Rana Ashkar, and Michael F. Brown

Introduction 772
 Neutron spin echo spectroscopy of lipid membranes 775

Solid-state ^2H NMR spectroscopy of lipid membranes	782
Membrane stiffening effect of cholesterol from molecular dynamics simulations	788
Cholesterol effects on drug uptake and drug delivery applications	789
Conclusions	790
References	791

30. Cholesterol in drug delivery systems

DanRong Hu and ZhiYong Qian

Introduction	798
The common synthesis chemistry of modifying cholesterol into the polymers	799
Cholesterol in the form of drug delivery vehicles	801
Conclusion	817
References	817

31. Modification of vascular receptor pharmacology by cholesterol: From molecular determinants to impact on arterial function

Alex M. Dopico, Anna N. Bukiya, and Kelsey C. North

Introduction	826
Cholesterol modulation of vasoactive drug action in which the underlying pharmacodynamic process(es) is not fully determined	827
Cholesterol modulation of vasoactive drug action occurring at the cell membrane where the vasoactive drug receptor of interest is embedded	834
Cholesterol modulation of vasoactive drug action occurring at the vasoactive drug receptor protein itself	839
Conclusions and prospective	844
References	845

32. Clinical strategies for reducing cholesterol levels

Claude K. Lardinois and Samantha Karr

Introduction	854
Epidemiology	854
Major guidelines for lipid-lowering therapy in the United States	856

Pharmacologic treatment of lipids	864
Other lipid-lowering therapies	883
Nonprescription and dietary supplements	886
Patient education	890
Clinical pearls	890
Screening for lipid disorders	891
Summary	892
References	893

33. Medicinal chemistry and pharmacology of statins

Bob M. Moore, II and George A. Cook

Introduction	903
Medicinal chemistry of statins	905
Pharmacology	919
Future drugs and concluding remarks	922
References	922

34. Cyclodextrins as promising therapeutics against cholesterol overload

Florina Zakany, Tamas Kovacs, Lajos Szente, and Zoltan Varga

Introduction	929
Cyclodextrins in general	930
Cyclodextrins in the treatment of Niemann-Pick type C disease	934
Cyclodextrins with great potential in the treatment of neurodegenerative diseases	941
Cyclodextrins as promising therapeutics in atherosclerosis	947
Role of cyclodextrins in the treatment of kidney diseases	951
Role of cyclodextrins in the treatment of eye disorders	952
Potential effects of cyclodextrins against coronavirus	953
Concluding remarks	954
References	955

35. Hyperlipidemia and rheumatoid arthritis

Aliki I. Venetsanopoulou, Paraskevi V. Voulgari, and Alexandros A. Drosos

Introduction	970
Pathophysiologic mechanisms in rheumatoid arthritis (RA)	971
Articular and extra-articular manifestations of RA	972

Rheumatoid arthritis treatment	973	Other agents	984
Comorbidities in RA	974	Mediterranean diet and RA	986
CVD: A major comorbidity in RA	974	The role of exercise in RA	986
CVD risk assessment in RA	975	Conclusions	987
CVD and atherosclerosis in RA	975	References	987
Lipid profile in RA patients	978		
Mechanisms related to dyslipidemia in RA	979	36. Management of hypercholesterolemia	
Lipid concentration and inflammatory markers	979	in individuals living with HIV/AIDS	
Atherosclerosis and inflammation	979	Musaab Ahmed, Marium Ahmed, Dushyant Mital, and	
Lipid metabolism and inflammation	980	Mohamed H. Ahmed	
The impact of cytokines on LDL	980		
Lipid peroxidation	980	Introduction	1000
Altered HDL function and structure	981	Nucleoside reverse transcriptase inhibitors	
Effects of antirheumatic therapy on serum lipid		(NRTIs)	1002
levels	981	Nonnucleoside reverse transcriptase inhibitors	
Glucocorticoids (GCs)	981	(NNRTIs)	1002
DMARDs	982	Diabetes mellitus, metabolic syndrome and HIV	1004
Antitumor necrosis factor-alpha (anti-TNF-a)		Conclusion	1012
agents	983	References	1013
Anti-interleukin-6 (IL-6) agents	984		
Janus kinase inhibitors (JAK inhibitors)	984	Index	1021

Cholesterol chemistry and laboratory synthesis

Hélio M.T. Albuquerque^a, Clementina M.M. Santos^{a,b},
and Artur M.S. Silva^a

^aLAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Aveiro, Portugal ^bCentro de Investigação de Montanha (CIMO), Instituto Politécnico de Bragança, Bragança, Portugal

Abbreviations

Ac	acetyl
ABSA	acetamidobenzenesulfonyl azide
BBN	9-borabicyclo[3.3.1]nonane
Bn	benzyl
Bu	butyl
COSY	correlation spectroscopy
DEPT	distortionless enhancement by polarization transfer
DMSO	dimethylsulfoxide
DMF	<i>N,N</i> -dimethylformamide
DMAP	4-dimethylaminopyridine
Et	ethyl
HMBC	Heteronuclear Multiple Bond Correlation
HSQC	Heteronuclear Single Quantum Coherence
HMPA	hexamethylphosphoramide
IUPAC	International Union of Pure and Applied Chemistry
LDA	lithium diisopropylamide
Me	methyl
MMC	magnesium methyl carbonate
Ms	methanesulfonyl (often shortened to mesyl)
NMR	nuclear magnetic resonance
NOESY	Nuclear Overhauser Effect Spectroscopy
<i>p</i>	<i>para</i>
PCC	pyridinium chlorochromate
Pd/C	palladium on carbon
Ph	phenyl
Py	pyridine
<i>t</i>	<i>tert</i>
TBSCl	<i>tert</i> -butyldimethylsilyl chloride

THF	tetrahydrofuran
TMS	tetramethylsilane
Ts	toluenesulfonyl (often shortened to tosyl)

Introduction

The name cholesterol derives from the Ancient Greek chole- (bile) and stereos (solid), followed by the chemical suffix of the functional group alcohol (-ol). Known also by the name cholesterin, cholesteryl alcohol, cholest-5-en-3 β -ol, among others, this interesting natural molecule is a type of modified sterol belonging to the heterogeneous group of organic compounds known as lipids. With a bulky, rigid, and asymmetric structure, the cholesterol skeleton possesses four fused rings aligned from A to D, corresponding to three six-membered and one five-membered. As a whole, the four rings comprise the 1,2-cyclopentane perhydrophenanthrene system (Fig. 1A) (Nes, 2011). The rings are *trans*-connected and create an almost planar structure (Fig. 1C). The C-18 and C-19 methyl substituents are linked at C-10 and C-13, in relative *cis* configuration. Due to this structural prolife, the flat face of cholesterol is called the smooth α -face, and all substituents located on this face (in *trans*-conformation relative to C-19) are called α , while the substituents located on the rough β -face (presence of the two methyl substituents) are called β (in *cis*-conformation relative to C-19). The cholesterol moiety bears an additional polar 3 β -hydroxy group and a C5=C6 double bond in B-ring (Róg, Pasenkiewicz-Gierula, Vattulainen, & Karttunen, 2009).

From a chemical point of view, the cholesterol molecule comprises four essential domains (Fig. 1B). The 3-hydroxy group of domain I constitutes not only an important active site for hydrogen bond interactions with several biological molecules but also a versatile functional group for derivatization. In domain II, the absence of methyl groups at C-4 and C-14 influences the planarity of the molecule, and the C5=C6 double bond is an attractive carbon center to several addition reactions. The natural (*R*)-configuration at C-20 observed in domain III determines the “right-handed” conformation of the side chain, while in domain IV, the conformation and length of the side chain are of high importance to intermolecular contacts (Cerqueira et al., 2016). The recommended name by the International Union of Pure and Applied Chemistry (IUPAC) for natural cholesterol is (3*S*,8*S*,9*S*,10*R*,13*R*,14*S*,17*R*)-10,13-dimethyl-17-[(*R*)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1*H*-cyclopenta[*a*]phenanthren-3-ol. In its pure state, it is a white and crystalline powder




FIG. 1 (A) Cholesterol tetracyclic nucleus with numbering of carbon atoms and rings labelling; (B) cholesterol four structural domains; (C) cholesterol crystal structure obtained from <https://www.ccdc.cam.ac.uk/structures/search?id=doi:10.5517/cc6d1t&sid=DataCite>.

that is odorless and tasteless, with a melting point of 148–149°C (“[cholesterol],”, 2016; Barton, 1976).

Historically, the first identification of cholesterol is attributed to the French chemist François Poulletier de la Salle, who collected it as a crystalline component from human gallstones, in 1769. In 1815, the chemist Michel Eugène Chevreul isolated a crystalline compound of bile stones and named it cholesterine, which was renamed to cholesterol after knowing that the substance was a secondary alcohol. The correct chemical formula of $C_{27}H_{45}O$ was only proposed in 1888 by F. Reinitze, and the first steric representations of the molecule were published by Heinrich Wieland and Adolf Windaus, their efforts leading the two scientists to win the Nobel Prize in Chemistry in 1927 and 1928, respectively (Nes, 2011). The steroid nucleus proposed by Wieland in his Nobel lecture presented some limitations. In 1932, however, his research group corrected it to the skeleton known nowadays (Vaupel, 2007). The research in steroids by Konrad Bloch and Feodor Lynen granted them the Nobel Prize in Physiology or Medicine in 1964, for their discoveries concerning the mechanism and regulation of cholesterol and fatty acid metabolism. Later in 1985, Michael S. Brown and Joseph L. Goldstein were also awarded with the Nobel Prize in Physiology or Medicine for their findings relating to the regulation mechanisms of cholesterol metabolism (“Feodor Lynen—Biographical, 2021,” “Joseph L. Goldstein—Biographical, 2021,” “Konrad Bloch—Biographical, 2021,” “Michael S. Brown—Biographical, 2021”).

Cholesterol is synthesized by all animal cells and is an essential structural component of animal cell membranes, where it contributes to the order of phospholipid chains and overall membrane (dis)order, integrity and heterogeneity. It is also used as a precursor for the biosynthesis of steroid hormones, bile acids and vitamin D (Cerqueira et al., 2016; Ercole, Whittaker, Quinn, & Davis, 2015; Róg et al., 2009). Although cholesterol has eight stereocenters (Fig. 1B) that could rise to 256 stereoisomers, only the natural enantiomer with the (3*R*,20*R*)-configurations, is used as a membrane constituent (Xu et al., 2005).

As an amphiphilic molecule, having a hydrophobic hydrocarbon body and a hydrophilic hydroxy headgroup, cholesterol occupies a position at polar-nonpolar interfaces, as observed in cell membranes. The crystal structure of one form of cholesterol monohydrate published by Craven (1976) is based on a local pseudosymmetry arrangement of eight independent molecules in the triclinic cells, similar to the structure reported by Shieh, Hoard, and Nordman (1977) for anhydrous cholesterol crystals at room temperature (25°C). This molecular packing in the crystal structures is in some way in line to the tendency toward double layer structures with an end-for-end arrangement of nearly parallel molecules (Bernal, Crowfoot, & Fankuchen, 1940). On the other hand, cholesterol crystals at 37°C have a remarkably large unit cell containing 16 independent cholesterol molecules, and the transition preserves a closely obeyed pseudosymmetry present in the structure (Hsu & Nordman, 1983). Garti et al. studied phase transitions in cholesterol crystallized from various solvents, characterizing the effect of several solvents (e.g., carbon tetrachloride, acetonitrile, methanol, ethanol) and conditions of crystallization (Garti, Karpuij, & Sarig, 1980). Using differential thermal analysis, infrared spectroscopy and polarization microscopy, Barton had found that the phase transitions of cholesterol and other sterols subjected to heating and cooling in a range of –20°C to +150°C were dependent on the state of hydration and on the structure of the aliphatic side chain (Barton, 1976).

Below, we will review major milestones in characterization of cholesterol structure, cholesterol laboratory synthesis, and synthetic routes for production of enantiomeric cholesterol.

Cholesterol structural characterization

In 1973, Barry et al. used 1D ^1H nuclear magnetic resonance (NMR) experiments to assign unequivocally the chemical shifts of the A and B ring protons of cholesterol using deuterated chloroform (CDCl_3) as solvent (Table 1) (Barry et al., 1973). Years later, Sawan et al. performed ^1H NMR spectrum of cholesterol in pyridine- d_5 to accomplish the same goal (Sawan et al., 1979). Since then, several 1D and 2D NMR techniques have been used to complete ring proton assignment of various steroids by comparison with cholesterol data (Drew, Brisson, Morand, & Szabo, 1987; Zipser et al., 1998).

The latest NMR characterization of cholesterol dates back to 1998, and therefore, with more than 20 years passed by, we were encouraged to get our own 1D (^1H , ^{13}C , DEPT 90, and DEPT 135) and 2D NMR (HSQC, HMBC, COSY, and NOESY) data for the commercial cholesterol molecule, presenting the ^1H and ^{13}C NMR spectra as standard reference (Figs. 2 and 3). Our own interpretation of NMR data, based on the obtained 1D and 2D NMR, is listed in Tables 1 and 2, with unequivocal assignments of almost all carbons. Carbons C-7, C-11, C-13, C-15, C-16, and C-23 were assigned by analogy with previous reported data (*) (Table 2).

Although the assignment of ^{13}C NMR chemical shifts in a molecule as large as cholesterol is a challenging task, some research groups dedicated their efforts to achieve this goal (ApSimon, Beierbeck, & Saunders, 1973; Mantsch & Smith, 1973; Reich, Jautelat, Messe,

TABLE 1 ^1H chemical shifts of cholesterol in several deuterated solvents.^a

H	$\text{CDCl}_3^{\text{b,c}}$	Pyridine- $d_5^{\text{b,c}}$	CDCl_3^{d}	CDCl_3^{e}
1 α , 1 β	–	1.83	–	–
2 α	1.90	2.07	1.50	–
2 β	1.58	1.80	–	–
3 α	3.47	3.82	3.39	3.47–3.57 (m)
4 α , 4 β	2.3	2.60	2.13	2.17–2.33 (m)
6	5.30	5.41	5.34	5.34–5.36 (m)
7 α , 7 β	2.05	2.03	1.95	–
8	–	–	1.5	–
18- CH_3	0.68 ^c	–	0.72	0.67 (s)
19- CH_3	1.02 ^c	–	1.02	1.00 (s)
21- CH_3	–	–	0.94	0.91 (d, $J=6.5\text{ Hz}$)
26- CH_3	–	–	0.87	0.862 (d, $J=6.6\text{ Hz}$) or 0.858 (d, $J=6.6\text{ Hz}$)
27- CH_3	–	–	–	–

^aChemical shifts in ppm relative to the internal standard, tetramethylsilane (TMS).

^bBarry, Dobson, Sweigart, Ford, and Williams (1973).

^cSawan, James, Gruenke, and Craig (1979).

^dZipser, Bradford, and Hollingsworth (1998).

^eOur own data ^1H NMR (300 MHz).




FIG. 2 ^1H NMR spectrum of cholesterol (CDCl_3 , 300 MHz).




FIG. 3 ^{13}C NMR spectrum of cholesterol (CDCl_3 , 75 MHz).

TABLE 2 ¹³C chemical shifts of cholesterol in several deuterated solvents.^a

C	CDCl ₃ ^{b,c}	CDCl ₃ ^c	CDCl ₃ ^d	CDCl ₃ ^e (DEPT 135, DEPT 90)	CCl ₄ ^{b,c}	Benzene- <i>d</i> ₆ ^{b,c}	Pyridine- <i>d</i> ₅ ^{b,c}	1,4-Dioxane- <i>d</i> ₄ ^{b,c}
1	38.6	37.3	37.2	37.2 (CH ₂)	38.6	38.0	38.4	38.2
2	32.8	31.6	31.6	31.7 (CH ₂)	32.6	32.4	32.7	32.7
3	72.8	71.6	71.8	71.8 (CH)	72.1	71.9	71.6	71.8
4	43.5	42.2	42.3	42.3 (CH ₂)	43.5	43.2	43.8	43.5
5	142.1	140.6	140.6	140.7	142.1	141.6	142.4	142.4
6	122.7	121.4	121.4	121.7 (CH)	122.3	121.8	121.5	121.7
7	33.1	31.9	31.9	31.9 ^f (CH ₂)	33.1	32.6	32.7	32.7
8	33.1	31.9	31.9	31.9 (CH)	33.1	32.6	33.0	32.7
9	51.4	50.2	50.2	50.1 (CH)	51.4	50.9	51.0	51.3
10	37.6	36.5	36.5	36.5	37.6	37.0	37.4	37.4
11	22.3	21.1	21.1	21.1 ^f (CH ₂)	22.3	21.7	21.9	21.9
12	41.0	39.8	39.8	39.8 (CH ₂)	41.0	40.4	40.8	40.7
13	43.4	42.3	42.3	42.3 ^f	43.3	43.0	43.0	43.2
14	58.0	56.8	56.8	56.8 (CH)	58.0	57.2	57.4	57.8
15	25.5	24.3	24.3	24.3 ^f (CH ₂)	25.4	24.8	25.0	25.0
16	29.4	28.3	28.3	28.2 ^f (CH ₂)	29.4	24.8	29.0	29.0
17	57.4	56.2	56.1	56.1 (CH)	57.4	56.9	57.0	57.2
18	13.1	11.9	11.9	11.9 (CH ₃)	13.1	12.3	12.5	12.4
19	20.6	19.4	19.4	19.4 (CH ₃)	20.6	19.8	20.1	19.9
20	37.0	36.8	35.8	35.8 (CH)	37.0	36.5	36.8	36.8
21	20.0	18.8	18.7	18.7 (CH ₃)	20.0	19.3	19.5	19.4
22	37.4	36.2	36.2	36.2 (CH ₂)	37.4	37.0	37.0	37.2
23	25.1	23.9	23.8	23.8 ^f (CH ₂)	25.1	24.6	24.7	24.7
24	40.7	39.5	39.5	39.5 (CH ₂)	40.7	40.2	40.2	40.3
25	29.2	28.0	28.0	28.0 (CH)	29.1	28.6	28.7	29.0
26	23.9	22.6	22.6	22.6 or 22.8 (CH ₃)	23.9	23.1	23.1	23.1
27	24.1	22.8	22.8	22.8 or 22.6 (CH ₃)	24.1	23.3	23.5	23.3

^aChemical shifts in ppm relative to the internal standard, tetramethylsilane (TMS).^bMantsch and Smith (1973).^cBlunt and Stothers (1977).^dSmith (1978).^eOur own data ¹³C NMR (75 MHz).^fAssigned by analogy to previous publications.

Weigert, & Roberts, 1969; Smith, 1978; Smith, Deavenport, Swanzy, & Pate, 1973). Blunt and Stothers covered the ^{13}C NMR assignments of cholesterol in several deuterated solvents (Blunt & Stothers, 1977) and the chemical shifts are presented in Table 2. The 27 carbon atoms of cholesterol are characterized to possess mainly nonpolar atoms (24 out of the 27), a polar atom corresponding to C-3 and the unsaturated carbons corresponding to C5=C6 double bond, in a total range of 130 ppm. From analyzing the data shown in Table 2 we can state that the chemical shifts vary slightly with the solvent used in the acquisition and even using the same solvent, the data can be quite different according to the research group.

Based on a more detailed analyzes on the data provided by Mantsc et al., the most solvent-sensitive positions are the 3-OH and C-6, both of which are shifted by about 1 ppm in CDCl_3 and about 0.5 ppm in CCl_4 , for higher frequency values, when compared to benzene- d_6 , pyridine- d_5 , and 1,4-dioxane- d_4 (Table 2).

Cholesterol laboratory synthesis

Cholesterol total synthesis—Historical perspective

The total synthesis of cholesterol was one of the most remarkable achievements of 20th century Chemistry. An upmost historical curiosity is that the laboratory synthesis of cholesterol was some sort of a mental competition between Robinson in Oxford and Woodward at Harvard. The interesting outcome was that both research groups, simultaneously and independently, achieved the cholesterol total synthesis in 1951 (Cardwell, Cornforth, Duff, Holtermann, & Robinson, 1951; Woodward, Sondheimer, & Taub, 1951a). According to chemistry historian Mulheirn (2000), the preliminary notice of Robinson's total synthesis was published in *Chemistry and Industry* in 1951 (Cardwell et al., 1951), only a couple of weeks after Woodward's announcement of his own synthesis at the Chemical Society Centenary Lecture (subsequent preliminary notice of the synthesis was published in the *Journal of the American Chemical Society*) (Woodward, Sondheimer, Taub, Heusler, & McLamore, 1952). Despite Robinson substantial contributions to synthetic organic chemistry (Robinson annulation is perhaps the most well-known), Woodward was able to complete his project in a remarkably short period (around 2 years), which was testimony both to his brilliance and to the pharmaceutical industry financial support.

The Woodward synthesis itself can be described as a $\text{C} \rightarrow \text{CD} \rightarrow \text{BCD} \rightarrow \text{ABCD}$ route (Fig. 4), rather than the $\text{BC} \rightarrow \text{ABC} \rightarrow \text{ABCD}$ route (Fig. 5) used by Robinson. Woodward was able to gather support of industry to not only fund human resources but also supply key intermediates; Robinson's synthesis in turn had to resort to using relays. Many of chemical intermediates of Robinson's synthesis were already known and available from natural sources, and therefore, Robinson's challenge was to proof that these intermediates could be linked to each other via chemical synthesis, in order to develop a formal cholesterol total synthesis. From a practical point of view, and despite that all steroid intermediates of Robinson's relay approach were already known, his linear cholesterol synthesis requires 68 reaction steps, (Cardwell et al., 1951; Cardwell, Cornforth, Duff, Holtermann, & Robinson, 1953; Cornforth & Robinson, 1946, 1949) in opposition to Woodward's with "only" 35 steps (Woodward et al., 1952; Woodward, Sondheimer, and Taub, 1951a, 1951b; Woodward, Sondheimer, Taub, Heusler, & McLamore, 1951).


Woodward's cholesterol total synthesis

FIG. 4 Retrosynthetic analysis of Woodward's cholesterol total synthesis.





FIG. 5 Retrosynthetic analysis of Robinson's cholesterol total synthesis.


Woodward's cholesterol total synthesis

The retrosynthetic analysis of Woodward's approach could sometimes be misunderstood, since the D ring remains D-homo until the last step of ring construction ([Scheme 2](#)) and the required 5-membered ring was obtained only after a ring contraction; it could also be termed as $C \rightarrow BC \rightarrow ABC \rightarrow ABCD$. Whatever the case, Woodward's starting point was 5-methoxy-2-methyl-1,4-quinone **1**, used to form ring C in the final structure. The Diels-Alder reaction of hydroquinone **1** with butadiene **2** gave the *cis*-bicycle **3**, which was converted to the *trans*-isomer **4** through sodium enolate followed by acidification ([Scheme 1](#)). Reduction with lithium aluminum hydride (LiAlH_4) followed by dehydration gave ketol **6**, which upon deoxygenation of its acetate with zinc gave enone **8** ([Scheme 1](#)). Claisen condensation of enone **9** followed by Michael addition of ethyl vinyl ketone originates dione **10**, which undergoes cyclization with KOH to produce tricycle **11** ([Scheme 1](#)). The following steps of Woodward's synthesis involve the diol **12** formation with osmium tetroxide (OsO_4), subsequent diol protection with acetone and copper(II) sulfate (CuSO_4), hydrogenation and Claisen condensation to give **15**




SCHEME 1 Woodward's cholesterol total synthesis: preparation of Christmasterone **21**.

(Scheme 1). The enamine protection followed by Michael addition of cyanoethylene and subsequent nitrile hydrolysis gave the carboxylic acid **18** (Scheme 1). Lactonization of carboxylic acid **19**, followed by Grignard reaction with methylmagnesium bromide (MeMgBr), and subsequent aldol condensation gave the tetracyclic ketone **21** (Scheme 1), which completes the four-ring structure required for cholesterol synthesis. Tetracyclic ketone **21** (nicknamed "Christmasterone") was obtained on Christmas Day in 1950 by Sondheimer, and it was a top-most example of Woodward's high-pressure style of leadership combined with the sense of success being just around the corner. At this point, the final hurdle was the contraction of ring D from a six-membered to a five-membered ring.



SCHEME 2 Woodward's cholesterol total synthesis: preparation of cholestanol **36**.

Treatment of Christmasterone **21** with periodic acid (HIO_4) in 1,4-dioxane followed by heating the product **22** in the presence of a catalytic amount of piperidine acetate gave DL- $\Delta^{9(11),16}$ -bisdehydro-20-norprogesterone **23** (Scheme 2), from which a route to cholesterol was known. The sodium dichromate ($\text{Na}_2\text{Cr}_2\text{O}_7$) oxidation of the aldehyde function of **23** gave carboxylic acid **24**, which upon diazomethane esterification, hydrogenation and oxidation gave ketone **27** (Scheme 2). The sodium borohydride (NaBH_4) ketone reduction, ester hydrolysis, and secondary alcohol acetylation with acetic anhydride gave carboxylic acid **30** (Scheme 2). The final stages of Woodward's synthesis were focused on the preparation of C-17 aliphatic side chain. The thionyl chloride (SOCl_2) treatment of carboxylic acid **30** gave the corresponding acyl chloride **31**, which upon methyl cadmium (MeCd) and Grignard reaction with isohexylmagnesium bromide afforded diol **33** (Scheme 2). Three reaction steps later, involving dehydration, hydrogenation and ester hydrolysis, cholestanol **36** was obtained (Scheme 2). The conversion of cholestanol **36** into cholesterol **41** was already demonstrated, involving five additional



SCHEME 3 Cholestanol 36 conversion into cholesterol 41 following Dauben and Eastham method.


reaction steps (Scheme 3). The oxidation of cholestanol 36 to the corresponding ketone 37 and further selective C-4 bromination and elimination gave cholestenone 39 (Scheme 3).

The conversion of cholestenone 39 into cholesterol 41 was accomplished by the method of Dauben and Eastham reported in 1950 (Dauben & Eastham, 1950). The treatment of cholestenone 39 with acetyl chloride in acetic anhydride gave the enol acetate 40 which, without purification, was reduced by sodium borohydride and potassium hydroxide to yield natural cholesterol 41, upon fractionation with digitonin for the isolation of the correct isomer (Scheme 3) (Birch, 1950; Dauben & Eastham, 1950; Djerassi & Scholz, 1948; Kritchevsky, Garmaise, & Gallagher, 1952; Ruzicka, Plattner, & Aeschbacher, 1938).

Robinson's cholesterol total synthesis

As Robinson used a BC \rightarrow ABC \rightarrow ABCD synthetic approach (Fig. 5), his starting material was 1,6-dihydroxynaphthalene 42 (corresponding to B and C rings in the final cholesterol structure), which was converted in the tricyclic structure 43 in a five reaction steps protocol (addition of A ring) (Scheme 4).

The synthesis of the first relay molecule 44 (also known as Reich diketone) (Reich, 1945) was completed 12 steps later (Scheme 4). The second relay molecule 45 was prepared resorting to eight additional reaction steps. Interestingly, this differed from the first one in "only" a double bond in ring B and the 3-hydroxy group replacing the original carbonyl group (Scheme 4). Resorting to another 12 reaction steps, Robinson prepared his third relay molecule 46, *en route* to the fourth relay 47, which has already ring D of the final cholesterol structure (Scheme 4).




SCHEME 4 Robinson's cholesterol **36** total synthesis, based on a relay approach.

Two more relays were synthesized, molecules **48** and **49**, being the final 12 reaction steps used to add the cholesterol tail. Thus, he resorted to a similar strategy to that used by Woodward (Scheme 4).^a The conversion of cholesterol **36** into cholesterol **41**, followed the same already known methodology depicted in Scheme 3.

Cholesterol hemisynthesis

The introduction of cholesterol side chain at C-20 is quite a challenge, as can be understood either from Woodward's or Robinson's total syntheses. An interesting approach, however, was developed by Schmuff and Trost (1983), based on organocuprate-mediated methods. This strategy started from the natural dehydroepiandrosterone **50** which was further converted in alcohol **51** in three reaction steps (Scheme 5). Then, the Moffatt-type oxidation gave the (*E*)-enone **52**, which upon reaction with lithium diisohexylcuprate gave cholestanone **53**

^a A relay molecule can be defined as a compound which needs to be synthesized for the first time in total synthesis methodologies, but once synthesized, it is necessary to have it available in larger quantities from natural sources. This strategy saves many valuable man-hours synthesizing the relay substrates in the laboratory, because for every experiment that is successful, there are many that are not, and so a large amount of substrate is needed at each stage in the synthesis.



SCHEME 5 Alkylcuprate-mediated synthetic route to cholesterol from dehydroepiandrosterone 50.

as the only detectable C-20 isomer (Scheme 5). Subsequent Wolff-Kishner reduction gave the isocholesterol methyl ether 54, which was further converted into cholesterol (Scheme 5).

Synthesis of *ent*-cholesterol: The unnatural enantiomer

All known natural sterols have the same absolute configuration at the C-10 and C-13 quaternary centers, and so there is no simple way to convert readily available natural sterols into their enantiomeric series. Therefore, the preparation of *ent*-cholesterol (the unnatural enantiomer of cholesterol) (Fig. 6) is only possible through enantioselective total synthesis.

The *ent*-cholesterol 55 total synthesis was reported for the first time in 1992 by Rychnovsky and Mickus (1992). They took as inspiration an elegant stereoselective synthesis of 19-nor steroids by a group at Hoffmann-La Roche, and prepared *ent*-testosterone 64 as chemical intermediate for the synthesis of *ent*-cholesterol (Scheme 6). The achiral triketone 56 was used as starting material for the enantioselective intramolecular aldol reaction followed by acid-catalyzed elimination to give the chiral enedione 57 (Scheme 6). The stereogenic center in dione 57 was employed to control the remaining stereocenters in the final *ent*-cholesterol. The NaBH_4 reduction of the saturated ketone followed by protection with isobutylene gave enone 58, which upon treatment with Stille's reagent delivers the carboxylic acid 59 (Scheme 6). Hydrogenation and reaction with





FIG. 6 Structures of cholesterol and *ent*-cholesterol.





SCHEME 6 Synthesis of *ent*-testosterone **64**, intermediate in the synthesis of *ent*-cholesterol **55**.

aqueous formaldehyde gave the enone **60**, which upon Robinson annulation with β -keto ester **61** gave the tricyclic intermediate **62** (Scheme 6). The 19-methyl group was introduced through enone reduction followed by treatment with iodomethane to give ketone **63** (Scheme 6). The acid catalyzed cyclization of ketone **63** gave the required *ent*-testosterone **64** (Scheme 6).

Once *ent*-testosterone **64** was obtained, Rychnovsky and Mickus were able to reach *ent*-cholesterol in a few reaction steps (Scheme 7). They obtained the β,γ -unsaturated ketone **65** in acidic media, which upon reduction with $\text{LiAl}(\text{OtBu})_3\text{H}$ followed by OH-protection with *tert*-butyldimethylsilyl chloride (TBSCl) gave the monosilyl diol **67** (Scheme 7). The stereochemistry at C-17 and C-20 was set by hydroboration with 9-borabicyclo[3.3.1]nonane (9-BBN) which enters from the top face of the alkene. Coupling the resulting hindered trialkylborane with chloroacetonitrile in the presence of a hindered base gave nitrile **69** as a single isomer (Scheme 7). The side chain was completed by nitrile alkylation with 1-bromo-3-methylbutane and reductive decyanation followed by desilylation to afford *ent*-cholesterol (Scheme 7).


An alternative methodology to convert *ent*-testosterone into *ent*-cholesterol was reported later in 1999 by Kumar and Covey (1999). To do so, Kumar and Covey used the previously reported methodology to prepare steroid **67** from *ent*-testosterone **64** (Scheme 7). However, they faced successive experimental failures building up the side chain of *ent*-cholesterol, and therefore they were forced to consider an alternative strategy to complete the synthesis (Scheme 8).

The Kumar and Covey strategy relied on the ene reaction of (*Z*)-olefin **70** with 4-methylpent-1-enal which gave the epimeric alcohol **71** (Scheme 8). The selective reduction

SCHEME 7 Synthesis of *ent*-cholesterol from *ent*-testosterone **64** precursor.SCHEME 8 Alternative method for the preparation of *ent*-cholesterol from *ent*-testosterone.

of Δ^{16} -double bond of **71** gave the C-22 epimers of steroid **72**, which upon a tosylation/detosylation method gave steroid **74** (Scheme 8). The final removal of TBS protecting group with Bu_4NF gave *ent*-cholesterol **55** (Scheme 8).

As demonstrated earlier in this chapter, the common synthetic strategies for the synthesis of either cholesterol or *ent*-cholesterol proceed via the initial construction of the steroid ring system followed by the subsequent introduction of the C-17 side chain. This type of synthetic strategies is not suitable for preparing ^{13}C -labeled *ent*-cholesterols because the isotopic labels have to be incorporated before the multiple steps involved in construction of the side chain are initiated. In this sense, Jiang and Covey proposed in 2002 the total synthesis of *ent*-cholesterol by a route which starts with construction of the sterol D-ring containing the cholesterol side chain and then proceeds via elaboration of the sterol C, B, and A rings, respectively (Jiang & Covey, 2002). Accordingly, they started with methyl acetoacetate **75** which was converted in three steps into racemic compound **76** (Scheme 9). The addition of 4-methylpentylmagnesium

SCHEME 9 *ent*-Cholesterol total synthesis reported by Jiang and Covey.

bromide to β -keto ester **76** gave racemic product **77**, which upon transesterification with (*R*)-pantolactone gave a diastereomeric mixture from which diastereomer **78** was easily separated (Scheme 9). At this point, the side chain of *ent*-cholesterol was already incorporated, and subsequent reaction with methyl vinyl ketone gave the intermediate compound **79**, thus setting the proper chemical features of what will become the C-ring, and also formation of the 18-methyl group (Scheme 9). *p*-Toluenesulfonic acid (*p*-TsOH) catalyzes the cyclization of intermediate **79** to give enone **80**, which upon reaction with ethylene glycol was converted into ketal **81** (Scheme 9). The (*R*)-pantolactone group of compound **81** was then reduced using LiAlH_4 and upon three additional reaction steps, the 18-methyl group with proper stereochemistry was established in compound **83** (Scheme 9). The removal of the ketal protecting group from **83** yielded the desired C,D ring-side chain fragment, indenone **84** (Scheme 9). The reaction between indenone **84** and magnesium methyl carbonate (MMC) in DMF, followed by COOH methylation gave the keto ester **85**, used to stabilize the keto acid obtained from reaction with MMC (Scheme 9). Hydrogenation using 5% Pd/BaSO₄ gave saturated keto ester **86**, which was subsequently converted in compound **90**, in four steps so that the remaining rings of *ent*-cholesterol could be built (Scheme 9). Next, displacement of the mesylate group of compound **90** by the anion formed from methyl 6-(2-methyl-1,3-dioxolan-2-yl)-3-oxohexanoate **91**, followed by cyclization gave compound **92** (Scheme 9). The introduction of the 19-methyl group of *ent*-cholesterol into precursor enone **92** was made by reduction followed by lithium enolate intermediate reaction with excess iodomethane to give compound **93**, which upon cyclization rendered *ent*-cholestenone **94** (Scheme 9). The conversion of *ent*-cholestenone **94** to *ent*-cholesterol **55** was achieved via the dienol acetate, which was then reduced with NaBH_4 to give *ent*-cholesterol **55** (Scheme 9).

Sixteen years later from Rychnovsky first synthesis of *ent*-cholesterol **55**, his group reported a new concise and scalable synthesis of the unnatural enantiomer of cholesterol, starting from (*S*)-citronellol (Fig. 7) (Belani & Rychnovsky, 2008). The Rychnovsky new synthesis of *ent*-cholesterol **55** is based on a ring D to C to B to A approach and incorporates the cholesterol side chain early in the synthetic procedure, as in the strategy reported in 2002 by Jiang and Covey.

The first key intermediates **C** and **B** were synthesized following a C–H insertion strategy (Fig. 7 and Scheme 10). Commercially available (*S*)-citronellol was converted to the corresponding benzenesulfonate and subsequently alkylated with the dianion of methyl





FIG. 7 Retrosynthetic analysis of *ent*-cholesterol starting from (*S*)-citronellol.

SCHEME 10 Synthesis of *ent*-cholesterol from (*S*)-citronellol.

acetoacetate to give β -keto ester **96** (Scheme 10). A diazo transfer reaction allowed the conversion of β -keto ester **96** into α -diazo- β -keto ester **97**, which upon diastereoselective C–H insertion reaction gave the keto ester **98** (Scheme 10). The C–H insertion strategy drastically shortens the synthesis of the sterol side chain and allows the C-20 stereogenic center to be introduced from a chiral pool source. Hydrogenation of keto ester **98** using palladium on carbon (Pd/C) provided compound **99** with a saturated side chain, which subsequently underwent methylation followed by decarbomethoxylation to give α -methyl ketone **101** as a single diastereomer (Scheme 10). The Robinson annulation of ketone **101** with methyl vinyl ketone gave the corresponding Michael adduct which, upon treatment with *p*-TsOH, provided the enone **102** (CD rings completed) (Scheme 10). The strategy for the conversion of enone **102** to *ent*-cholesterol was the same double annulation strategy developed by Hoffmann La Roche, similar to that used by Rychnovsky in his first *ent*-cholesterol synthesis (Rychnovsky & Mickus, 1992). Therefore, the treatment of enone **102** with Stile's reagent gave the carboxylic acid **103**, which upon hydrogenation and subsequent reaction with formaldehyde followed by the addition of thiophenol gave thioether **104** (Scheme 10). The annulation of thioether **104** with β -keto ester **91** provided the tricyclic enone **105**, which upon reduction and alkylation installed the C-19 methyl group stereoselectively (Scheme 10). Acid-catalyzed deprotection of the ketal followed by aldol condensation provided the A ring of *ent*-cholestenone. The AB ring functionality was modified by deprotonation using *t*BuOK, followed by kinetic protonation to provide the deconjugated ketone and diastereoselective reduction of the ketone with Li(O*t*Bu)₃AlH gave *ent*-cholesterol (Scheme 10) (Belani & Rychnovsky, 2008).

Concluding remarks

Cholesterol is an essential component of animal cell membranes and the precursor for the synthesis of steroid hormones and bile acids. The interest of scientist and industry in steroids, particularly cholesterol, dates back to the 1930s as these compounds were widely used in medicine. Steroids were big business in the pharmaceutical industry and a company that discovered viable ways to produce them stood to make huge profits. At that time, steroids were exclusively obtained through chemical conversion of steroid precursors extracted from natural sources in very expensive and unproductive processes. As a consequence, a general belief that completes synthesis might provide a cheaper and quicker method of production of steroids started to grow, even though complete synthesis might require over 30 stages. It is no coincidence, though, that one of the most significant chemical problems of that time drew the attention of two of the greatest chemists of the 20th century: Sir Robert Robinson at Oxford and R.B. Woodward at Harvard. Cholesterol was the most complex organic molecule synthesized up to that time, and its total synthesis paved the way for the synthesis of many related steroid hormones. Since 1951, there was no significant developments in cholesterol synthesis, with only one example of hemisynthesis from dehydroepiandrosterone through organocuprate-mediated methods. Interestingly enough, in recent years, cholesterol unnatural enantiomer—*ent*-cholesterol, has drawn much more attention than cholesterol itself. In fact, the scientific applications of *ent*-cholesterol as a tool to study the enantioselectivity of cholesterol interactions or the molecular recognition of cholesterol stereoisomers by monoclonal antibodies, for example, drove the development of three total synthetic routes to it within 18 years' time lapse. Noteworthy is the synthesis of

Jiang and Covey which allows the preparation of ^{13}C - and ^2H -labeled forms of *ent*-cholesterol, introduced near the end of the reaction sequence. This route is of particular importance for NMR studies of *ent*-cholesterol interactions. Apart from that, cholesterol has more interest in Chemistry as synthon to create cholesterol-based new molecules for a wide range of applications ranging from drug delivery or bioimaging applications to cholesterol-based liquid crystals and gelators (Albuquerque, Santos, & Silva, 2019).

References

- [cholesterol]. (2016). *IUPAC standards online*. De Gruyter. <https://www.degruyter.com/document/database/IUPAC/entry/iupac.compound.5997/html>.
- Albuquerque, H. M. T., Santos, C. M. M., & Silva, A. M. S. (2019). Cholesterol-based compounds: Recent advances in synthesis and applications. *Molecules*, 24(1), 116.
- ApSimon, J. W., Beierbeck, H., & Saunders, J. K. (1973). Lanthanide shift reagents in ^{13}C nuclear magnetic resonance: Quantitative determination of pseudocontact shifts and assignment of ^{13}C chemical shifts of steroids. *Canadian Journal of Chemistry*, 51(23), 3874–3881. <https://doi.org/10.1139/v73-578>.
- Barry, C. D., Dobson, C. M., Sweigart, D. A., Ford, L. E., & Williams, R. J. P. (1973). The structure of a cholesterol: Shift reagent complex in solution. In R. E. Sievers (Ed.), *Nuclear magnetic resonance shift reagents* (pp. 173–195). Academic Press.
- Barton, P. G. (1976). Phase transitions of sterols and sterol—Lecithin sterol—Lecithin mixtures. *Chemistry and Physics of Lipids*, 16(3), 195–200. [https://doi.org/10.1016/0009-3084\(76\)90026-8](https://doi.org/10.1016/0009-3084(76)90026-8).
- Belani, J. D., & Rychnovsky, S. D. (2008). A concise synthesis of Ent-cholesterol. *Journal of Organic Chemistry*, 73(7), 2768–2773. <https://doi.org/10.1021/jo702694g>.
- Bernal, J. D., Crowfoot, D., & Fankuchen, I. (1940). X-ray crystallography and the chemistry of the steroids. Part I. *Philosophical Transactions of the Royal Society of London. Series A, Mathematical and Physical Sciences*, 239(802), 135–182. <https://doi.org/10.1098/rsta.1940.0010>.
- Birch, A. J. (1950). 476. A conversion of cholest-4-en-3-one into cholesterol. *Journal of the chemical society*, 2325–2326. <https://doi.org/10.1039/JR95000002325>.
- Blunt, J. W., & Stothers, J. B. (1977). ^{13}C N.M.R. spectra of steroids—A survey and commentary. *Organic Magnetic Resonance*, 9(8), 439–464. <https://doi.org/10.1002/mrc.1270090802>.
- Cardwell, H. M. E., Cornforth, J. W., Duff, S. R., Holtermann, H., & Robinson, R. (1951). *Chemistry & industry*, 389–390.
- Cardwell, H. M. E., Cornforth, J. W., Duff, S. R., Holtermann, H., & Robinson, R. (1953). 76. Experiments on the synthesis of substances related to the sterols. Part LI. Completion of the syntheses of androgenic hormones and of the cholesterol group of sterols. *Journal of the Chemical Society*, 361–384. <https://doi.org/10.1039/JR9530000361>.
- Cerqueira, N. M., Oliveira, E. F., Gesto, D. S., Santos-Martins, D., Moreira, C., Moorthy, H. N., et al. (2016). Cholesterol biosynthesis: A mechanistic overview. *Biochemistry*, 55(39), 5483–5506. <https://doi.org/10.1021/acs.biochem.6b00342>.
- Cornforth, J. W., & Robinson, R. (1946). 139. Experiments on the synthesis of substances related to the sterols. Part XLV. *Journal of the Chemical Society*, 676–679. <https://doi.org/10.1039/JR9460000676>.
- Cornforth, J. W., & Robinson, R. (1949). 396. Experiments on the synthesis of substances related to the sterols. Part XLVIII. Synthesis of a tricyclic degradation product of cholesterol. *Journal of the Chemical Society*, 1855–1865. <https://doi.org/10.1039/JR9490001855>.
- Craven, B. M. (1976). Crystal structure of cholesterol monohydrate. *Nature*, 260(5553), 727–729. <https://doi.org/10.1038/260727a0>.
- Dauben, W. G., & Eastham, J. F. (1950). On the conversion of cholestenone to cholesterol. *Journal of the American Chemical Society*, 72(5), 2305. <https://doi.org/10.1021/ja01161a532>.
- Djerassi, C., & Scholz, C. R. (1948). Brominations with pyridine hydrobromide perbromide. *Journal of the American Chemical Society*, 70(1), 417–418. <https://doi.org/10.1021/ja01181a508>.
- Drew, J., Brisson, J.-R., Morand, P., & Szabo, A. G. (1987). ^1H and ^{13}C nuclear magnetic resonance assignment of fluorescent olefinic sterol derivatives for use as membrane probes. *Canadian Journal of Chemistry*, 65(8), 1784–1794. <https://doi.org/10.1139/v87-300>.

- Ercole, F., Whittaker, M. R., Quinn, J. F., & Davis, T. P. (2015). Cholesterol modified self-assemblies and their application to nanomedicine. *Biomacromolecules*, 16(7), 1886–1914. <https://doi.org/10.1021/acs.biomac.5b00550>.
- Feodor Lynen—Biographical. (2021). *NobelPrize.org*. <https://www.nobelprize.org/prizes/medicine/1964/lynen/biographical/> (Retrieved Friday 23 April 2021, from Nobel Media AB).
- Garti, N., Karpuij, L., & Sarig, S. (1980). Phase transitions in cholesterol crystallized from various solvents. *Thermochimica Acta*, 35(3), 343–348. [https://doi.org/10.1016/0040-6031\(80\)87134-6](https://doi.org/10.1016/0040-6031(80)87134-6).
- Hsu, L. Y., & Nordman, C. E. (1983). Phase transition and crystal structure of the 37 degrees C form of cholesterol. *Science*, 220(4597), 604. <https://doi.org/10.1126/science.6836303>.
- Jiang, X., & Covey, D. F. (2002). Total synthesis of ent-cholesterol via a steroid C,D-ring side-chain synthon. *Journal of Organic Chemistry*, 67(14), 4893–4900. <https://doi.org/10.1021/jo025535k>.
- Joseph L. Goldstein—Biographical. (2021). *NobelPrize.org*. <https://www.nobelprize.org/prizes/medicine/1985/goldstein/biographical/> (Retrieved Thursday 22 April 2021, from Nobel Media AB).
- Konrad Bloch—Biographical. (2021). *NobelPrize.org*. <https://www.nobelprize.org/prizes/medicine/1964/bloch/biographical/> (Retrieved Friday 23 April 2021, from Nobel Media AB).
- Kritchevsky, T. H., Garmaise, D. L., & Gallagher, T. F. (1952). Partial synthesis of compounds related to adrenal cortical hormones. XVI. Preparation of cortisone and related compounds. *Journal of the American Chemical Society*, 74(2), 483–486. <https://doi.org/10.1021/ja01122a060>.
- Kumar, A. S., & Covey, D. F. (1999). A new method for the preparation of Ent-cholesterol from Ent-testosterone. *Tetrahedron Letters*, 40(5), 823–826. [https://doi.org/10.1016/S0040-4039\(98\)02588-X](https://doi.org/10.1016/S0040-4039(98)02588-X).
- Mantsch, H. H., & Smith, I. C. P. (1973). A study of solvent effects on the ¹³C nuclear magnetic resonance spectra of cholesterol, pyridine, and uridine. *Canadian Journal of Chemistry*, 51(9), 1384–1391. <https://doi.org/10.1139/v73-207>.
- Michael S. Brown—Biographical. (2021). *NobelPrize.org*. <https://www.nobelprize.org/prizes/medicine/1985/brown/biographical/> (Retrieved Friday 23 April 2021, from Nobel Media AB).
- Mulheim, G. (2000). Robinson, Woodward and the synthesis of cholesterol. *Endeavour*, 24(3), 107–110. [https://doi.org/10.1016/S0160-9327\(00\)01310-7](https://doi.org/10.1016/S0160-9327(00)01310-7).
- Nes, W. D. (2011). Biosynthesis of cholesterol and other sterols. *Chemical Reviews*, 111(10), 6423–6451. <https://doi.org/10.1021/cr200021m>.
- Reich, H. (1945). Über bestandteile der nebennierenrinde und verwandt stoffe. 72. Mitteilung. Oxydation von desoxycholsäure-methylester-diacetat mit chromsäure. III. Untersuchung der “ketonfreien” anteile. *Helvetica Chimica Acta*, 28(1), 892–897. <https://doi.org/10.1002/hlca.194502801127>.
- Reich, H. J., Jautelat, M., Messe, M. T., Weigert, F. J., & Roberts, J. D. (1969). Nuclear magnetic resonance spectroscopy. Carbon-13 spectra of steroids. *Journal of the American Chemical Society*, 91(26), 7445–7454. <https://doi.org/10.1021/ja01054a037>.
- Róg, T., Pasenkiewicz-Gierula, M., Vattulainen, I., & Karttunen, M. (2009). Ordering effects of cholesterol and its analogues. *Biochimica et Biophysica Acta*, 1788(1), 97–121. <https://doi.org/10.1016/j.bbammem.2008.08.022>.
- Ruzicka, L., Plattner, P. A., & Aeschbacher, R. (1938). Über sterioide und sexualhormone. 44. Mitteilung. Zur abspaltung von bromwasserstoff aus 2-brom-cholestanon und 2-brom-androstandion. *Helvetica Chimica Acta*, 21(1), 866–872. <https://doi.org/10.1002/hlca.193802101113>.
- Rychnovsky, S. D., & Mickus, D. E. (1992). Synthesis of ent-cholesterol, the unnatural enantiomer. *Journal of Organic Chemistry*, 57(9), 2732–2736. <https://doi.org/10.1021/jo00035a036>.
- Sawan, S. P., James, T. L., Gruenke, L. D., & Craig, J. C. (1979). Proton NMR assignments for cholesterol. Use of deuterium NMR as an assignment aid. *Journal of Magnetic Resonance*, 35(3), 409–413. [https://doi.org/10.1016/0022-2364\(79\)90063-5](https://doi.org/10.1016/0022-2364(79)90063-5).
- Schmuff, N. R., & Trost, B. M. (1983). Organocuprate-mediated methods for the stereospecific introduction of steroid side chains at C-20. *Journal of Organic Chemistry*, 48(9), 1404–1412. <https://doi.org/10.1021/jo00157a002>.
- Shieh, H. S., Hoard, L. G., & Nordman, C. E. (1977). Crystal structure of anhydrous cholesterol. *Nature*, 267(5608), 287–289. <https://doi.org/10.1038/267287a0>.
- Smith, W. B. (1978). Carbon-13 NMR spectroscopy of steroids. In G. A. Webb (Ed.), *Vol. 8. Annual reports on NMR spectroscopy* (pp. 199–226). Academic Press.
- Smith, W. B., Deavenport, D. L., Swanzey, J. A., & Pate, G. A. (1973). Steroid ¹³C chemical shifts. Assignments via shift reagents. *Journal of Magnetic Resonance*, 12(1), 15–19. [https://doi.org/10.1016/0022-2364\(73\)90096-6](https://doi.org/10.1016/0022-2364(73)90096-6).
- Vaupel, E. (2007). Interconnections and independence: Heinrich Wieland (1877–1957) and his era. *Angewandte Chemie International Edition*, 46(48), 9154–9179. <https://doi.org/10.1002/anie.200702255>.

- Woodward, R. B., Sondheimer, F., & Taub, D. (1951a). The total synthesis of cholesterol. *Journal of the American Chemical Society*, 73(7), 3548. <https://doi.org/10.1021/ja01151a556>.
- Woodward, R. B., Sondheimer, F., & Taub, D. (1951b). The total synthesis of some naturally occurring steroids. *Journal of the American Chemical Society*, 73(7), 3547–3548. <https://doi.org/10.1021/ja01151a555>.
- Woodward, R. B., Sondheimer, F., Taub, D., Heusler, K., & McLamore, W. M. (1951). The total synthesis of a steroid1. *Journal of the American Chemical Society*, 73(5), 2403–2404. <https://doi.org/10.1021/ja01149a562>.
- Woodward, R. B., Sondheimer, F., Taub, D., Heusler, K., & McLamore, W. M. (1952). The total synthesis of steroids1. *Journal of the American Chemical Society*, 74(17), 4223–4251. <https://doi.org/10.1021/ja01137a001>.
- Xu, F., Rychnovsky, S. D., Belani, J. D., Hobbs, H. H., Cohen, J. C., & Rawson, R. B. (2005). Dual roles for cholesterol in mammalian cells. *Proceedings of the National Academy of Sciences of the United States of America*, 102(41), 14551. <https://doi.org/10.1073/pnas.0503590102>.
- Zipser, B., Bradford, J. J., & Hollingsworth, R. I. (1998). Cholesterol and its derivatives, are the principal steroids isolated from the leech species *Hirudo medicinalis*. *Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology*, 120(2), 269–282. [https://doi.org/10.1016/S0742-8413\(98\)10005-1](https://doi.org/10.1016/S0742-8413(98)10005-1).

CHOLESTEROL

From Chemistry and Biophysics to the Clinic

Edited by

Anna N. Bukiya, PhD, and Alex M. Dopico, MD, PhD

With ***CHOLESTEROL: From Chemistry and Biophysics to the Clinic***, Professors Anna Bukiya and Alex Dopico have compiled a comprehensive resource on both biological and clinical aspects of cholesterol, spanning the biophysics and biochemistry of this very special lipid, as well as the latest pharmacological discoveries used to tackle human disorders associated with abnormal cholesterol levels. Early chapters on basic sciences offer insights on the fundamental role of cholesterol in biological membranes, lab chemistry, cholesterol metabolism and synthesis, molecular evolution of cholesterol and sterols, and cholesterol modulation of membrane-spanning peptides, ion channels and receptors. Chapters on cellular and organismal development discuss blood cholesterol levels, cholesterol transport by lipoproteins and cholesterol metabolism, the role of cholesterol in early human development, and the contribution of genetics and nutrition to hypercholesterolemia. Pathophysiology specialists review familial hypobetalipoproteinemia, critical illness and cholesterol levels, coronary artery disease, cholesteryl ester storage disease, Niemann-Pick disease type C, cholesterol and viral pathology, cholesterol and neurodegenerative disorders, and the links of cholesterol to substance use disorders, using alcohol as an example. The final section examines the pharmacology of cholesterol-containing drug delivery systems, the impact of cholesterol on the effect of anesthetics and drug receptors in the cardiovascular system, and clinical strategies for reducing cholesterol levels. The section also introduces the reader to the future of cholesterol-lowering drugs based on cyclodextrins and highlights several examples when clinical management of cholesterol levels faces challenges in specific patient populations, such as patients who have rheumatoid arthritis and HIV.

Key Features

- Ties basic biology to clinical application and drug discovery
- Provides a one-stop source of information from bench to bedside
- Examines the latest pharmacological advances used to tackle cholesterol-related disorders
- Includes chapters contributed by a wide range of specialists, uniting various disciplines



ACADEMIC PRESS

An imprint of Elsevier

elsevier.com/books-and-journals

ISBN 978-0-323-85857-1



9 780323 858571